What Molecular Partners Ag does.

We are a clinical-stage biotechnology company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. We have programs in various stages of preclinical and clinical development, currently with main focus on oncology. DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of custom-built protein drug candidates based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. We believe the key properties of DARPins – potential for high affinity and specificity, small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. We leverage the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers.

Our DARPin candidates have been extensively tested in preclinical studies and clinical trials, including in more than 2,500 patients, and have been observed to be highly active and generally well-tolerated.

Revenue and profit, by fiscal year.

More on MOLN.

• Molecular Partners Ag summary
• Molecular Partners Ag financial statements
• Molecular Partners Ag key metrics
• Molecular Partners Ag health scores and style box
• Molecular Partners Ag earnings
• Molecular Partners Ag dividends
• Molecular Partners Ag valuation
• Molecular Partners Ag ownership and insiders
• Molecular Partners Ag peers

Figures from Molecular Partners Ag's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.